Drugs / ELK-003
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06713434 | May 2024 → Jun 2026 overdue | junctional epidermolysis bullosa, recessive dystrophic epidermolysis bullosa | Fundación DEBRA Chile, Niños Piel de Cristal | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ELK-003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06713434 ↗ |
| Route | Topical | “ELK-003 eye drops” NCT06713434 ↗ |